Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2484772 | Journal of Pharmaceutical Sciences | 2013 | 12 Pages |
Abstract
Basic guidance on the photostability testing of pharmaceuticals, designed to cover manufacturing and storage over shelf life, has long been established within ICH Q1(ICH,B10, but the guideline does not cover the photostability of drugs during or after administration (i.e., under conditions of use). To date, there has been a paucity of guidance covering the additional testing that would be of value during the clinical preparation and use of products. This commentary suggests a systematic approach, based on realistic “worst case” photoexposure scenarios and the existing ICH Option 1 and 2 light sources, to provide valuable data to pharmaceutical manufacturers and compounding pharmacists for the safe and effective use of photosensitive injection products. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:3888-3899, 2013
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Steven W. Baertschi, David Clapham, Chris Foti, Patrick J. Jansen, Solveig Kristensen, Roberta. Reed, Allen C. Templeton, Hanne Hjorth Tonnesen,